机构：[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[2]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[3]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[4]Deep Underground Space Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[5]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院
Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical
response rate to vaccines remains < 30%. Nanoparticles stabilize vaccines and improve antigen recognition and presentation,
resulting in high tumor penetration or accumulation, effective co-distribution of drugs to the secondary
lymphatic system, and adaptable antigen or adjuvant administration. Such vaccine-like nanomedicines have the ability
to eradicate the primary tumors as well as to prevent or eliminate metastases. This review examines state-of-theart
nanocarriers developed to deliver tumor vaccines to metastases, including synthetic, semi-biogenic, and biogenic
nanosystems. Moreover, it highlights the physical and pharmacological properties that enhance their anti-metastasis
efficiency. This review also addresses the combination of nanovaccines with cancer immunotherapy to target various
steps in the metastatic cascade, drawing insights from preclinical and clinical studies. The review concludes
with a critical analysis of the challenges and frameworks linked to the clinical translation of cancer nanovaccines.
基金：
This work was supported by grants from the National Natural Science Foundation
of China (No. 82202989, No. 32401087); Sichuan Science and Technology
Program (No. 2023YFS0163, No. 2023NSFSC1742); and Sichuan Province
Science and Technology Activities Funding for Returned Overseas Scholars
(awarded to Lingling Zhu) for financial support.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|1 区医学
小类|1 区血液学1 区肿瘤学
第一作者：
第一作者机构：[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China[2]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China[3]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China
推荐引用方式(GB/T 7714)：
Feng Tang,Hu Jia,Wen Jirui,et al.Personalized nanovaccines for treating solid cancer metastases[J].Journal Of Hematology & Oncology.2024,17(1):115.doi:10.1186/s13045-024-01628-4.
APA：
Feng Tang,Hu Jia,Wen Jirui,Qian Zhiyong,Che Guowei...&Zhu Lingling.(2024).Personalized nanovaccines for treating solid cancer metastases.Journal Of Hematology & Oncology,17,(1)
MLA：
Feng Tang,et al."Personalized nanovaccines for treating solid cancer metastases".Journal Of Hematology & Oncology 17..1(2024):115
医学